Malignant Pleural Mesothelioma Clinical Trial
Official title:
Trimodality Therapy for Malignant Pleural Mesothelioma: Radical Pleurectomy, Followed by Adjuvant Chemotherapy With Cisplatin/Pemetrexed and Radiotherapy
The role of surgical resection in the management of Malignant Pleural Mesothelioma (MPM) is
still controversial. The selection criterion to perform either Extrapleural Pneumonectomy
(EPP) or Pleurectomy/Decortication (P/D) is dependent not only on the cardio-pulmonary
status of the patient, tumor stage and intraoperative findings but also on surgeons'
decision and philosophy. There are no established guidelines. Radical Pleurectomy (RP)
competes against EPP as surgical therapy modality. Both surgical approaches are
cytoreductive treatment options. The aim is to remove all gross disease and to achieve
macroscopic complete resection.
Originally P/D was a palliative option for controlling pleural effusion. But lung-sparing
surgery for MPM seems to be an alternative to patients unsuitable or unwilling to undergo
EPP in a multimodality therapy concept. Most studies evaluating multimodality therapies for
MPM are based on retrospective analyses and their interpretation is difficult because of
inhomogeneous patient groups studied.
The aim of our study was to analyze the feasibility and results of RP as surgical therapy
modality in a standardized trimodality therapy concept.
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06037941 -
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma
|
N/A | |
| Completed |
NCT01675765 -
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
|
Phase 1 | |
| Withdrawn |
NCT04201145 -
Pembrolizumab + Defactinib In Pleural Mesothelioma
|
Phase 1 | |
| Completed |
NCT03048474 -
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
|
Phase 2 | |
| Completed |
NCT02369198 -
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
|
Phase 1 | |
| Terminated |
NCT01870609 -
Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
|
Phase 2 | |
| Active, not recruiting |
NCT00886028 -
Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
| Completed |
NCT00272558 -
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
|
Phase 2 | |
| Active, not recruiting |
NCT02436733 -
Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
|
Phase 2 | |
| Completed |
NCT04843007 -
Alvopem® (Pemetrexed) Safety Assessment
|
||
| Completed |
NCT01721018 -
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT00797719 -
Short Neoadjuvant Hemithoracic IMRT for MPM
|
Phase 1/Phase 2 | |
| Completed |
NCT00386815 -
Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
|
Phase 2 | |
| Recruiting |
NCT03715933 -
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
|
Phase 1 | |
| Completed |
NCT04775446 -
Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
|
||
| Completed |
NCT01644994 -
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
|
Phase 1/Phase 2 | |
| Completed |
NCT01865045 -
Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
|
||
| Completed |
NCT00571298 -
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
|
Phase 1 | |
| Active, not recruiting |
NCT04162015 -
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
|
Phase 1 | |
| Recruiting |
NCT04400539 -
The IMmunotherapy Pleural 5-ALA PDT
|
Phase 2 |